PHILADELPHIA, June 24, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, presented in vivo data demonstrating benefit on body weight, adiposity and blood glucose of ENT-03 compared to semaglutide in an obese, diabetic animal model, with persistence…Read More
Enterin Presents Data Demonstrating Strong Benefit of ENT03 on Body Weight Adiposity and Blood Glucose Vs Semaglutide in a Diet Induced Obesity Mouse Model
